Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data

Roche forayed into the obesity market when it acquired privately owned Carmot Therapeutics for $2.7 billion. CT-388 is one of the assets added by the company to its pipeline post this buyout. Roche also added other incretin-based obesity drug candidates, namely CT-996 and CT-868. While CT-996 is an oral formulation to treat obesity patients with and without T2D, CT-868 is intended to treat obese patients with type I diabetes (T1D). Per Roche, this recently acquired incretin-based portfolio could also be exp ...